Condition

Neuroblastoma clinical trials and research

• 67Clinical trials
• 106NIH research projects
• 1New in 30 days
• 30Countries

Newest Neuroblastoma clinical trials

All recruiting trials (67)

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Tracking tumor DNA over time in neuroblastoma

  This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07516678

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Personalized B7-H3 CAR T cells combined with PRAME antigen-specific T cells for relapsed embryonal tumors

  This trial tests a combined personalized B7-H3 CAR T cell and PRAME-specific T cell infusion after lymphodepleting chemotherapy in children and young adults with relapsed or refractory embryonal tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT07172958

• Detecting cancer cells in frozen ovarian or testicular tissue from children with neuroblastoma or Ewing sarcoma

  This project will test whether RT-qPCR or droplet digital PCR (ddPCR) better detects leftover neuroblastoma or Ewing sarcoma cells in frozen ovarian or testicular tissue from children treated during infancy.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand, Auvergne · NCT07141862

• IR-101 for relapsed or refractory neuroblastoma

  This trial will test whether IR-101, a targeted radiopharmaceutical, can safely treat children (age ≥12 months) and adolescents with relapsed or refractory high-risk neuroblastoma that shows MIBG uptake.

  Recruiting at 2 sites Early Phase 1 Sichuan University · Chengdu, Sichuang and 1 other locations · NCT07067346

• Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma

  This trial will test whether giving the immunotherapy Naxitamab more slowly, along with irinotecan, temozolomide, and sargramostim, reduces infusion side effects for people with relapsed or refractory neuroblastoma.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07027748

• rhIL-15 with dinutuximab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma in children and young adults

  This trial will test whether adding rhIL-15 to dinutuximab with irinotecan and temozolomide helps children and young adults (ages 3-35) whose neuroblastoma has returned or not responded to prior treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06995872

• Capmatinib treatment for adults with cancers having MET gene changes

  This study is testing if capmatinib, a drug for lung cancer, can help adults with different types of cancers that have changes in the MET gene.

  Recruiting at 16 sites Phase 2/3 Cancer Research UK · Belfast and 16 other locations · NCT06988475

• Intrathecal topotecan with maintenance chemotherapy after consolidation for high‑risk embryonal brain tumors in children under 6

  This study will test whether monthly intrathecal topotecan plus a year of oral maintenance chemotherapy after high‑dose consolidation is feasible and tolerable for children under 6 with high‑risk embryonal brain tumors.

  Recruiting at 12 sites Early Phase 1 C17 Council · Calgary, Alberta and 12 other locations · NCT06942039

• Combining arsenic trioxide, MAPK inhibitors, and chemotherapy for advanced neuroblastoma

  This study is testing a new combination of arsenic trioxide, MAPK inhibitors, and chemotherapy to see if it can help people with advanced neuroblastoma feel better and improve their treatment outcomes.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06933394

• Evaluating 18F-MFBG PET Imaging for Neuroblastoma

  This study is testing a new type of PET scan using a special dye to see if it can help doctors better diagnose and understand the extent of neuroblastoma in patients.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06852807

• Supportive care intervention for low-income children with high-risk neuroblastoma

  This study is testing a new supportive care program for low-income children with high-risk neuroblastoma to see if it helps them and their families feel better during treatment.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Hartford, Connecticut and 5 other locations · NCT06831552

• Hetrombopag for improving platelet recovery in children with neuroblastoma after stem cell transplant

  This study is testing if a new medication called hetrombopag can help children with neuroblastoma recover their platelet levels faster after a stem cell transplant.

  Recruiting Beijing Children's Hospital · Beijing · NCT06818916

• Using GD2-CAR T Cells to Treat Neuroblastoma

  This study is testing whether a new treatment using GD2-CAR T cells can help patients with neuroblastoma, especially those whose cancer has come back or hasn’t responded to other treatments.

  Recruiting Early Phase 1 The General Hospital of Western Theater Command · Chengdu, Sichuan · NCT06684639

• Understanding recovery in children after cancer surgery

  This study looks at how children aged 3-18 and their families recover after cancer surgery by using smartwatches and surveys to gather information over a year.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06674811

• Using umbilical cord blood NK cells to treat high-risk neuroblastoma in children

  This study is testing if using natural killer cells from umbilical cord blood can help children with high-risk neuroblastoma feel better and live longer when combined with other treatments.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06631391

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• Adding Naxitamab to chemotherapy for high-risk neuroblastoma

  This study is testing if adding a new treatment called Naxitamab to chemotherapy can help children with high-risk neuroblastoma respond better to their initial treatment and live longer.

  Recruiting Guangzhou Women and Children's Medical Center · Guanzhou, Guangdong · NCT06574698

• Using silmitasertib with chemotherapy for relapsed solid tumors

  This study is testing a new drug called silmitasertib combined with chemotherapy to see if it helps people with relapsed solid tumors feel better and manage their cancer.

  Recruiting at 24 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 23 other locations · NCT06541262

• Combining tipifarnib and naxitimab for treating relapsed neuroblastoma

  This study is testing a new combination of an oral drug called tipifarnib and an intravenous drug called naxitimab to see if it can help children with relapsed neuroblastoma.

  Recruiting at 12 sites Phase 2 Milton S. Hershey Medical Center · Little Rock, Arkansas and 11 other locations · NCT06540963

• Reduced chemotherapy and antibody treatment for children with high-risk neuroblastoma

  This study is testing a new, lighter chemotherapy and antibody treatment for children with high-risk neuroblastoma to see if it helps them get better.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT06528496

• Using modified T cells to treat certain solid tumors in children and young adults

  This study is testing a new treatment using modified T cells to see if it can help children and young adults with tough-to-treat solid tumors.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06500819

• Dinutuximab beta combined with two induction chemotherapy regimens for newly diagnosed high-risk neuroblastoma

  This will test different doses of dinutuximab beta given with two standard induction chemotherapy regimens in children (18 months to under 18 years) with newly diagnosed high‑risk neuroblastoma to find a safe recommended dose.

  Recruiting Phase 1 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06485947

• Eflornithine (DFMO) plus AMXT 1501 for neuroblastoma, CNS tumors, and sarcomas

  This trial tests whether adding the oral drug AMXT 1501 to oral DFMO can help children and young adults (diagnosed by age 21) with relapsed or refractory neuroblastoma, ETMR, ATRT, Ewing sarcoma, osteosarcoma, or newly diagnosed DIPG.

  Recruiting at 14 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 13 other locations · NCT06465199

• STING: sequential temozolomide, irinotecan, donor NK cells, and dinutuximab for neuroblastoma

  This will test whether adding donor TGF‑beta‑imprinted NK cells to dinutuximab plus temozolomide, irinotecan, and GM‑CSF helps children and young adults with relapsed or refractory high‑risk neuroblastoma.

  Recruiting at 8 sites Phase 2 New Approaches to Neuroblastoma Therapy Consortium · Los Angeles, California and 12 other locations · NCT06450041

• Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients

  This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.

  Recruiting at 70 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 70 other locations · NCT06395103

• Assessing surgical risk factors for laparoscopic surgery in abdominal neuroblastoma

  This study is trying to see how different factors affect the safety and success of laparoscopic surgery for children with abdominal neuroblastoma.

  Recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06296732

• Combining dinutuximab with chemotherapy and surgery for treating high-risk neuroblastoma in children

  This study is testing if adding a new medicine called dinutuximab to regular chemotherapy and surgery can help children with high-risk neuroblastoma live longer without their cancer coming back.

  Recruiting at 177 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 179 other locations · NCT06172296

• Induction chemotherapy combined with immunotherapy for high-risk neuroblastoma

  This study is testing a new treatment that combines chemotherapy with immunotherapy to see if it helps children and teens with high-risk neuroblastoma do better and live longer.

  Recruiting Phase 3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06071897

• Testing a vaccine with beta-glucan for high-risk neuroblastoma patients

  This study is testing a new vaccine combined with a substance called beta-glucan to see if it can help children with high-risk neuroblastoma who are in complete remission.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06057948

• Evaluating Naxitamab for Treating High-Risk Pediatric Neuroblastoma

  This study is testing a new treatment called naxitamab, alone or with other medicines, to see if it can help children with high-risk neuroblastoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06013618

• Molecular Characterization of Pediatric Brain Tumors and Neuroblastoma

  This study is trying to understand how radiation treatment affects brain tumors and neuroblastoma in kids by collecting samples and data from patients to see how their tumors behave and respond to treatment.

  Recruiting at 2 sites Brigham and Women's Hospital · San Francisco, California and 1 other locations · NCT06000787

• Creating immune organoids to study pediatric cancers

  This study is trying to create mini immune systems from kids' tissues to see how they respond to different types of pediatric cancers.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif and 1 other locations · NCT05890781

• Comparing two imaging methods for evaluating neuroblastoma in children

  This study is testing which imaging method works better for spotting neuroblastoma in children by comparing two different techniques.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT05826158

• Alectinib treatment for ALK-positive cancers in adults and children

  This study is testing if alectinib, a drug for lung cancer, can help treat different types of ALK-positive cancers in both adults and children.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05770037

• Treatment of recurrent or refractory neuroblastoma in children with APG-115 and APG-2575

  This study is testing a new treatment using two drugs, APG-115 and APG-2575, to see if they can help children with hard-to-treat neuroblastoma or solid tumors feel better.

  Recruiting at 3 sites Phase 1/2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 2 other locations · NCT05701306

• Naxitamab added to standard chemotherapy for high-risk neuroblastoma

  This study is testing if adding a new treatment called naxitamab to regular chemotherapy can help children with high-risk neuroblastoma do better and live longer.

  Recruiting at 25 sites Phase 2 Milton S. Hershey Medical Center · Birmingham, Alabama and 25 other locations · NCT05489887

• Using expanded gamma delta T cells with chemotherapy for treating relapsed neuroblastoma and osteosarcoma

  This study is testing if a new treatment using special immune cells along with chemotherapy can help children with relapsed neuroblastoma and osteosarcoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT05400603

• International registry and biobank for patients with peripheral neuroblastic tumors

  This study is setting up a global database and biobank for patients with peripheral neuroblastic tumors to gather important health information and samples that can help improve future treatments.

  Recruiting at 35 sites Institut Curie · Prague and 37 other locations · NCT05192980

• Using cabozantinib to prevent recurrence in high-risk pediatric solid tumors

  This study is testing if the drug cabozantinib can help prevent high-risk pediatric solid tumors, like neuroblastoma and sarcoma, from coming back after treatment.

  Recruiting at 6 sites Phase 2 Nationwide Children's Hospital · Birmingham, Alabama and 5 other locations · NCT05135975

• Using 18F-MFBG PET/CT to evaluate neural crest tumors

  This study is testing a new imaging method using 18F-MFBG to see if it can help diagnose and better understand tumors like pheochromocytoma, paraganglioma, and neuroblastoma in patients.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Dongcheng · NCT05069220

• Vaccine combined with β-glucan and GM-CSF for treating high-risk neuroblastoma

  This study is testing a new vaccine combined with two other treatments to see if it can help people with high-risk neuroblastoma who are in complete remission stay cancer-free longer.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04936529

• 177Lu-DOTATATE treatment for children with high-risk neuroblastoma

  This study is testing a new treatment called 177Lu-DOTATATE to see if it can help children with high-risk neuroblastoma that has come back or worsened.

  Recruiting at 9 sites Phase 2 Karolinska University Hospital · Copenhagen, Copenhagen and 8 other locations · NCT04903899

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

• Tegavivint treatment for recurrent or refractory solid tumors in children

  This study tests if a new intravenous medication called tegavivint can help children with tough-to-treat solid tumors, like Ewing sarcoma and desmoid tumors, by finding the right dose and seeing how well it works.

  Recruiting at 19 sites Phase 1/2 Children's Oncology Group · Birmingham, Alabama and 20 other locations · NCT04851119

• Precision medicine and cell therapy for children with brain and neuroblastoma cancers

  This study is testing a new treatment that combines targeted therapy with immune cell therapy to see if it helps children with tough brain cancers like DIPG and neuroblastoma.

  Recruiting at 2 sites Phase 1 University of Florida · Gainesville, Florida and 2 other locations · NCT04837547

• Optimizing PET Imaging with 18F-DOPA for Various Conditions

  This study is testing if a special imaging technique using 18F-DOPA can help doctors see and understand conditions like congenital hyperinsulinism, neuroblastoma, neuroendocrine tumors, Parkinson's disease, and Lewy body dementia better in both kids and adults.

  Recruiting Phase 3 University of Alberta · Edmonton, Alberta · NCT04706910

• Imaging neuroblastoma using 68Ga-DOTATATE

  This study is testing a new type of imaging called 68Ga-DOTATATE PET/CT to see if it works better and is safer than the standard method for detecting neuroblastoma in both children and adults.

  Recruiting at 2 sites Phase 2 Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Montreal, Quebec and 2 other locations · NCT04559217

• Combining vorinostat with chemotherapy for relapsed solid tumors and CNS cancers

  This study is testing if adding a drug called vorinostat to chemotherapy can help people with relapsed solid tumors and brain cancers feel better and improve their treatment outcomes.

  Recruiting Phase 1 New York Medical College · Valhalla, New York · NCT04308330

• CAR T-Cell Therapy for Neuroblastoma and Osteosarcoma

  This study is testing a new CAR T-cell therapy for children with hard-to-treat neuroblastoma and osteosarcoma to see if it can better fight their cancer while keeping them safe from serious side effects.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Atlanta, Georgia and 1 other locations · NCT03721068

• Registry for rare lung tumors and DICER1-related conditions

  This study is collecting information about rare lung tumors in children, like pleuropulmonary blastoma, to help doctors understand how these conditions develop and how to treat them better.

  Recruiting Children's Hospitals and Clinics of Minnesota · Minneapolis, Minnesota · NCT03382158

• Adding iobenguane I-131 or lorlatinib to intensive treatment for children and young adults with high-risk neuroblastoma

  This trial tests whether adding the radioactive drug iobenguane I-131 or the targeted drug lorlatinib to standard intensive therapy helps children and young adults with newly diagnosed high-risk neuroblastoma or nodular ganglioneuroblastoma stay free of disease longer.

  Recruiting at 153 sites Phase 3 Children's Oncology Group · Birmingham, Alabama and 163 other locations · NCT03126916

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

• Myeloablative chemotherapy and stem cell rescue for high-risk neuroblastoma

  This study is testing a new chemotherapy approach followed by a stem cell rescue to see if it helps children with high-risk neuroblastoma after their initial treatment.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT02605421

• Advanced therapy for high-risk neuroblastoma in children

  This study is testing a new combination of treatments for children with high-risk neuroblastoma to see if it helps them do better than the usual therapies.

  Recruiting at 24 sites Phase 2 Milton S. Hershey Medical Center · Birmingham, Alabama and 27 other locations · NCT02559778

• Transplantation with modified stem cells and Zoledronate for pediatric cancers

  This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.

  Recruiting Phase 1 University of Wisconsin, Madison · Madison, Wisconsin · NCT02508038

• Combination therapy with MM-398 liposome irinotecan and cyclophosphamide in children with solid tumors

  This study tests whether a higher dose of MM-398 (liposomal irinotecan) can be given safely when used with cyclophosphamide in children with recurring or treatment-refractory solid tumors.

  Recruiting at 5 sites Phase 1 South Plains Oncology Consortium · Cincinnati, Ohio and 4 other locations · NCT02013336

• Study of neuroblastoma cell characteristics and treatment outcomes

  This study is collecting samples from children with high-risk neuroblastoma to learn more about the disease and find better ways to treat it.

  Recruiting at 13 sites New Approaches to Neuroblastoma Therapy Consortium · Los Angeles, California and 16 other locations · NCT01587300

• Collecting and storing samples from children and adults with common childhood cancers

  This study is collecting and storing samples from children and adults with common childhood cancers to help researchers learn more about these diseases and find better treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Washington D.C., District of Columbia and 4 other locations · NCT01109394

• Analysis of molecular changes in endocrine tumors

  This study is trying to understand the differences between benign and cancerous endocrine tumors by looking at tissue samples from patients having surgery or biopsy, to help improve how these tumors are detected and treated.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01005654

• Understanding the genetic makeup of neuroblastic tumors and their impact on treatment outcomes

  This study is trying to see how the genetic features of neuroblastic tumors affect how aggressive they are and how well different treatments work for patients.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT00588068

• Using Iodine I 131 Metaiodobenzylguanidine to treat advanced neuroblastoma and pheochromocytoma

  This study is testing if a special treatment called Iodine I 131 Metaiodobenzylguanidine can help people with hard-to-treat neuroblastoma and pheochromocytoma feel better when other treatments haven’t worked.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT00107289

NIH-funded research (newest 40 of 106)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Computational and functional screens to find actionable neuroblastoma drivers

  Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.

  NIH research Duke University · Durham, United States · NIH-11446226

• Understanding ATRX in neuroblastoma: new protein functions and treatment clues

  A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11441037

• Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors

  A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11415786

• Bispecific antibodies to help kids fight neuroblastoma and brain tumors

  A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11413442

• ADEPT-STAR therapy for high risk neuroblastoma

  A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.

  NIH research Expression Therapeutics · Tucker, United States · NIH-11407954

• MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma

  A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11400285

• Rewired metabolism and immunosuppression in MYCN-driven neuroblastoma

  A researcher team will study how the MYCN gene changes metabolism and immune responses in high-risk neuroblastoma to find strategies that could help the disease respond to future therapies.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11398164

• Early sympathetic nerve development and infant neuroblastoma

  This project looks at how embryonic nerve cells grow and connect to help explain causes of infant neuroblastoma and some birth defects.

  NIH research Children's Mercy Hosp (Kansas City, Mo) · Kansas City, United States · NIH-11397244

• Personalized vaccines for high-risk neuroblastoma

  A pediatric cancer research grant aims to create customized vaccines that target specific tumor markers in children with high-risk neuroblastoma to help the immune system fight the cancer.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11391029

• Targeting small extracellular vesicles to curb neuroblastoma spread

  A study to see if blocking tiny bubbles released by neuroblastoma cancer cells can slow spread and make treatments work better for children with this cancer.

  NIH research Pennsylvania State Univ Hershey Med Ctr · Hershey, United States · NIH-11389617

• ABT-199–based therapies for neuroblastoma in adults and children

  A cancer researcher is testing venetoclax (a BCL-2 inhibitor) in neuroblastoma to see if it works better when combined with targeted drugs.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11387752

• Understanding and Fighting Neuroblastoma to Help Kids

  Aims to uncover how neuroblastoma starts and grows so new, gentler therapies can help children survive with fewer side effects.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11384828

• Tumor and immune signatures linked to GD2 therapy in kids with neuroblastoma

  A study in children with high‑risk neuroblastoma looks for immune system patterns that predict how well GD2 antibody therapy works.

  NIH research Emory University · Atlanta, United States · NIH-11384562

• cGAS-STING and immune responses for pediatric neuroblastoma

  A training-focused program to help a pediatric oncologist develop new immune-based approaches to treat neuroblastoma in children.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11382165

• Targeting a vulnerable splicing process to help neuroblastoma patients

  This grant aims to test a therapy that disrupts a cancer-specific splicing process to improve outcomes for children with high-risk neuroblastoma.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11382134

• Targeted radionuclide therapy to boost CAR T cells for neuroblastoma

  A doctor-researcher is developing a treatment that combines targeted radiation with CAR T cell therapy to improve outcomes for kids with neuroblastoma.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11379963

• Combination high-LET radiotherapy for relapsed neuroblastoma in children

  A new treatment approach uses high-linear-energy-transfer radiotherapy with novel ligands to target neuroblastoma that has returned or persisted in children.

  NIH research Washington University · Saint Louis, United States · NIH-11378537

• Combining retinoic acid with proteasome inhibitors to treat neuroblastoma

  This NIH grant tests a combination of retinoic acid and proteasome inhibitors to treat neuroblastoma in children.

  NIH research Children's Research Institute · Washington, United States · NIH-11371019

• Targeting KAT6A/B to boost GD2 immunotherapy against neuroblastoma

  A scientist team plans to test whether blocking KAT6A/B makes neuroblastoma cells more responsive to GD2-targeted immunotherapy, potentially helping children with this cancer.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11370738

• Dual-labeled imaging tracer to help surgeons remove neuroblastoma

  A new intraoperative imaging tracer is being developed to help surgeons identify neuroblastoma tumors and nearby critical structures during surgery, with the goal of safer and more complete tumor removal.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11367493

• CAR-NKT Cells to Treat Neuroblastoma in Children

  This grant funds research to develop CAR-NKT cell therapy for children with neuroblastoma, aiming to improve tumor killing and help those with resistant disease.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11366862

• Immunotherapy nanoparticles to help children with neuroblastoma

  A funding-supported project aims to move a new immune-boosting nanoparticle therapy closer to use for kids with high-risk neuroblastoma.

  NIH research Vanderbilt University · Nashville, UNITED STATES · NIH-11365122

• Targeting SWI/SNF activity to fight pediatric neuroblastoma

  A new research grant is exploring how turning off a cell machinery (SWI/SNF with BRG1) could kill neuroblastoma cancer cells in children.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11358430

• Early phase 211At-MIBG trials for children with neuroblastoma and adults with neuroendocrine cancers

  A phase 1/2 study tests a new radioactive therapy (211At-MIBG) for kids with neuroblastoma and adults with advanced neuroendocrine cancers to see if it can improve tumor control with acceptable safety.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11336905

• Cell lineage as a predictor of immune response in neuroblastoma

  Researchers are exploring how the cell type of a child’s neuroblastoma tumor may determine how well immune-based therapies work.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11323558

• How MYCN gene changes make neuroblastoma hide from the immune system

  Researchers are looking at whether MYCN-driven changes in tumor fats and T cell metabolism explain why high-risk neuroblastoma in children resists immune attacks.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11314587

• GPC2-targeted CAR T therapy for childhood neuroblastoma

  Developing improved GPC2-targeted CAR T cell treatments to help children with high-risk neuroblastoma avoid relapse.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11314486

• Targeting treatment resistance in high‑risk childhood neuroblastoma

  This program aims to find why high‑risk neuroblastoma stops responding to treatments and use those discoveries to develop better, more targeted therapies for children with aggressive disease.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11310011

• Blood test to track and predict neuroblastoma outcomes

  This project uses a blood test that looks for tumor DNA signals to help doctors predict outcomes and monitor children with neuroblastoma.

  NIH research University of Chicago · Chicago, United States · NIH-11309677

• Immune-cell exosomes and microRNAs against childhood neuroblastoma

  This project tests whether tiny particles called exosomes from activated natural killer immune cells, and the microRNAs they carry, can help kill neuroblastoma tumors in children.

  NIH research Children's Research Institute · Washington, United States · NIH-11305263

• CHAF1A's role in neuroblastoma development using a new mouse model

  A new NIH grant will study how the CHAF1A gene drives neuroblastoma, a childhood cancer, using a novel mouse model and advanced techniques.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11301336

• Understanding how social stress may worsen neuroblastoma in kids

  This grant looks at how chronic social stress from poverty and isolation might make neuroblastoma harder to treat in children and explores ways to counteract those effects.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11297000

• Understanding high-risk neuroblastoma cell types

  This project seeks to find how different cell states in high-risk childhood neuroblastoma change tumor behavior and response to chemotherapy.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11285447

• Drug-targetable epigenetic changes driving aggressive neuroblastoma

  Researchers are looking at whether drugs that change how genes are packaged (epigenetic drugs) can block aggressive neuroblastoma in children.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11258053

• Extra 17q chromosome and aggressive neuroblastoma

  Researchers are looking at how an extra copy of chromosome 17q makes neuroblastoma tumors grow faster and resist chemotherapy in children.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11252342

• Drugs aimed at the BPTF protein to treat neuroblastoma

  Developing drug-like molecules that block the BPTF protein to help children with aggressive neuroblastoma.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11252307

• Targeting a MYCN-linked weakness in childhood neuroblastoma

  This project tests whether a drug that blocks SUMOylation can weaken MYCN-driven high-risk neuroblastoma in children, alone or added to current maintenance therapy.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11250076

• Reading RNA in individual cells from high-risk childhood neuroblastoma

  This project uses long-read RNA sequencing on single tumor cells to find cancer-specific surface proteins that might become new immune therapy targets for children with high-risk neuroblastoma.

  NIH research Children's Hosp of Philadelphia · Philadelphia, United States · NIH-11248384

• Immune suppression in MYCN-driven neuroblastoma

  This project looks at why aggressive, MYCN-driven neuroblastoma in children weakens the immune system and how that might be reversed.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11238875

• Telomere maintenance patterns as prognostic clues in high-risk neuroblastoma

  This grant studies how the way cancer cells keep their chromosomes intact may predict outcomes for children with high-risk neuroblastoma and guide future treatments.

  NIH research Texas Tech University Health Scis Center · Lubbock, United States · NIH-11228627

Related topics

Quick answers

How many Neuroblastoma clinical trials are recruiting right now?

67, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (39 trials), China (13 trials), Canada (10 trials), Netherlands (4 trials), United Kingdom (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 15, Phase 2: 15, Phase 1/2: 7, Early Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →